U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H21N7O4S.C5H8O3
Molecular Weight 547.584
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIODAZOSIN LEVULINATE

SMILES

CC(=O)CCC(O)=O.COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N3CCN(CC3)C(=O)C4=NN=C(O4)SC

InChI

InChIKey=NIDVOMJMOVCWQI-UHFFFAOYSA-N
InChI=1S/C18H21N7O4S.C5H8O3/c1-27-12-8-10-11(9-13(12)28-2)20-17(21-14(10)19)25-6-4-24(5-7-25)16(26)15-22-23-18(29-15)30-3;1-4(6)2-3-5(7)8/h8-9H,4-7H2,1-3H3,(H2,19,20,21);2-3H2,1H3,(H,7,8)

HIDE SMILES / InChI

Molecular Formula C5H8O3
Molecular Weight 116.1152
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H21N7O4S
Molecular Weight 431.469
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Tiodazosin is a newly developed antihypertensive agent, structurally related to prazosin. Prazosin and tiodazosin administrated intravenously to anesthetized rats, are equally effective hypotensive agents, but that the hypotensive potency of prazosin is greater than that of tiodazosin. However, chronic administration of equivalent doses of the two compounds for 25 and 52 days via the drinking water indicated approximately equivalent, sustained reductions in blood pressure. Furthermore, at the end of the 52-day chronic dosing period tiodazosin caused appreciably less alpha-adrenergic receptor antagonist activity than prazosin as assessed by the norepinephrine dose-pressor response profiles.

Approval Year

PubMed

PubMed

TitleDatePubMed
The effect of alpha 1-acid glycoprotein on the pharmacological activity of alpha 1-adrenergic antagonists in rabbit aortic strips.
1991-08
Alteration in the pharmacologic activity of alpha 1 adrenergic antagonists by alpha-1-acid glycoprotein.
1989
Determination of tiodazosin concentrations in human plasma with a fluorescence high-performance liquid chromatographic method.
1985-07-12
[New hypotensive drugs].
1984-12-17
Cardiovascular adrenoreceptor function during compensatory and decompensatory hemorrhagic shock.
1984
Determinations of tiodazosin and levulinic acid from tablets by high-performance liquid chromatography.
1983-10
Non-competitive antagonism of the alpha-adrenoceptor-mediated fast component of contraction of rat aorta, by doxazosin and prazosin.
1983-10
Effects of tiodazosin, a new antihypertensive, hemodynamics and clinical variables.
1983-09
The bioavailability and disposition of tiodazosin levulinate in beagle dogs with a comparison to prazosin hydrochloride.
1983-03-01
Determination of tiodazosin in plasma and whole blood by high-performance liquid chromatography.
1982-06-11
Effect of BL-5111-A, prazosin and phentolamine on responses of canine cutaneous veins to adrenergic activation.
1980-04
Profile of a new prazosin congener, BL-5111A. Studies in the rat.
1980-01-01
In vitro comparison of the pre- and postsynaptic alpha adrenergic receptor blocking properties of prazosin and tiodazosin (BL5111).
1980
Effects of tiodazosin, praxosin, trimazosin and phentolamine on blood pressure, heart rate and on pre- and postsynaptic alpha-adrenergic receptors in the rat.
1980
Comparative first dose effects of prazosin and tiodazosin (BL-5111) in spontaneously hypertensive rats.
1979-01
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:34:39 GMT 2025
Edited
by admin
on Mon Mar 31 17:34:39 GMT 2025
Record UNII
21CC6UVV2J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BR-5111R
Preferred Name English
TIODAZOSIN LEVULINATE
Common Name English
PENTANOIC ACID, 4-OXO-, COMPD. WITH (4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(5-(METHYLTHIO)-1,3,4-OXADIAZOL-2-YL)METHANONE (1:1)
Systematic Name English
Code System Code Type Description
PUBCHEM
21312538
Created by admin on Mon Mar 31 17:34:39 GMT 2025 , Edited by admin on Mon Mar 31 17:34:39 GMT 2025
PRIMARY
EPA CompTox
DTXSID20998117
Created by admin on Mon Mar 31 17:34:39 GMT 2025 , Edited by admin on Mon Mar 31 17:34:39 GMT 2025
PRIMARY
FDA UNII
21CC6UVV2J
Created by admin on Mon Mar 31 17:34:39 GMT 2025 , Edited by admin on Mon Mar 31 17:34:39 GMT 2025
PRIMARY
CAS
76798-65-7
Created by admin on Mon Mar 31 17:34:39 GMT 2025 , Edited by admin on Mon Mar 31 17:34:39 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY